Firefly Neuroscience (AIFF)
NASDAQ:AIFF
Want to see AIFF full AI Analyst Report?
Top Page
Firefly Neuroscience
(NASDAQ:AIFF)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.50
▲(138.10% Upside)
Action:ReiteratedDate:04/23/26
The score is held back primarily by weak financial performance driven by large losses and sustained cash burn, despite a healthier 2025 balance sheet. Technical trends are supportive with price above key moving averages and positive momentum indicators. Corporate financing activity provides funding support but underscores ongoing dilution/financing risk, while valuation remains constrained by loss-making results.
Positive Factors
Stronger balance sheet (no debt, positive equity)
The company moved from negative equity to roughly $7.6M of positive equity with no reported debt, materially lowering solvency risk. A debt-free balance sheet improves financial flexibility and reduces interest obligations, giving more runway to execute strategy while limiting near-term refinancing pressure.
Negative Factors
Large, persistent cash burn
Sustained negative operating and free cash flow at multi-million dollar annual levels creates ongoing financing needs and limits self-funded growth. Continued cash burn forces management to prioritize fundraising over long-term investment choices and increases the likelihood of recurring dilution or constrained R&D/commercial expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Stronger balance sheet (no debt, positive equity)
The company moved from negative equity to roughly $7.6M of positive equity with no reported debt, materially lowering solvency risk. A debt-free balance sheet improves financial flexibility and reduces interest obligations, giving more runway to execute strategy while limiting near-term refinancing pressure.
Read all positive factors
Firefly Neuroscience (AIFF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.29M
Dividend YieldN/A
Average Volume (3M)316.76K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth-70.76%
EPS Growth13.87%
CountryUS
Employees13
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-2.64
Shares Outstanding14,793,075
10 Day Avg. Volume358,037
30 Day Avg. Volume316,761
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.51
Price to Sales (P/S)10.11
P/FCF Ratio-1.39
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue23.24
Enterprise Value/Gross Profit41.15
Enterprise Value/Ebitda-1.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Firefly Neuroscience Business Overview & Revenue Model
Company Description
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytic...
How the Company Makes Money
null...
Firefly Neuroscience Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.14M | 108.00K | 498.00K | 0.00 | 32.00K |
| Gross Profit | 645.00K | 41.00K | 498.00K | 0.00 | 32.00K |
| EBITDA | -19.55M | -10.32M | -2.58M | -3.20M | -3.82M |
| Net Income | -19.88M | -10.46M | -2.60M | -3.79M | -4.38M |
Balance Sheet | |||||
| Total Assets | 10.48M | 4.60M | 2.64M | 135.00K | 953.00K |
| Cash, Cash Equivalents and Short-Term Investments | 2.75M | 1.81M | 2.14M | 58.00K | 653.00K |
| Total Debt | 0.00 | 694.00K | 0.00 | 0.00 | 1.79M |
| Total Liabilities | 2.84M | 4.98M | 2.53M | 2.25M | 3.97M |
| Stockholders Equity | 7.64M | -375.00K | 109.00K | -2.11M | -3.01M |
Cash Flow | |||||
| Free Cash Flow | -8.32M | -6.57M | -2.56M | -2.89M | -3.82M |
| Operating Cash Flow | -8.19M | -6.16M | -2.17M | -2.89M | -3.82M |
| Investing Cash Flow | -2.49M | -477.00K | -386.00K | 262.00K | 1.60M |
| Financing Cash Flow | 11.62M | 6.30M | 4.64M | 2.04M | 2.04M |
Firefly Neuroscience Technical Analysis
Positive
1.05
Price Trends
1.49
Positive
1.36
Positive
1.97
Negative
Market Momentum
>-0.01
Positive
50.07
Neutral
29.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIFF, the sentiment is Positive. The current price of 1.05 is below the 20-day moving average (MA) of 1.89, below the 50-day MA of 1.49, and below the 200-day MA of 1.97, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.07 is Neutral, neither overbought nor oversold. The STOCH value of 29.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIFF.
Firefly Neuroscience Risk Analysis
Firefly Neuroscience disclosed 60 risk factors in its most recent earnings report. Firefly Neuroscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Firefly Neuroscience Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
53 Neutral | $3.97B | -127.47 | -38.33% | ― | 26.24% | 61.36% | |
52 Neutral | $29.29M | -0.58 | -229.99% | ― | -70.76% | 13.87% | |
49 Neutral | $105.44M | -8.98 | -104.27% | ― | ― | 60.12% | |
46 Neutral | $39.71M | -6.64 | -119.92% | ― | -0.38% | 37.91% |
* Technology Sector Average
AIFF
Firefly Neuroscience
1.98
-1.17
-37.14%
IRTC
Irhythm Technologies
129.16
20.57
18.94%
NMTC
NeuroOne Medical Technologies
4.70
0.99
26.79%
CGTX
Cognition Therapeutics
1.18
0.73
162.22%
Firefly Neuroscience Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Firefly Neuroscience Completes Additional Private Equity Financing
Positive
Apr 22, 2026
On April 16, 2026, Firefly Neuroscience, Inc. completed an additional private placement closing under its March 8, 2026 Securities Purchase Agreement, issuing 5,333,333 units to an accredited investor at $1.50 per unit for total proceeds of $8 mil...
Private Placements and FinancingRegulatory Filings and Compliance
Firefly Neuroscience Completes Private Placement and Lock-Up Agreements
Positive
Mar 12, 2026
On March 8, 2026, Firefly Neuroscience, Inc. entered into a securities purchase agreement with accredited investors to sell up to 13.5 million units at $1.50 per unit, combining common stock or pre-funded warrants with additional warrants at highe...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Firefly Neuroscience Launches ATM Equity Program to Fund Growth
Positive
Feb 4, 2026
On February 3, 2026, Firefly Neuroscience launched a $7.43 million at-the-market equity program with Konik Capital Partners to bolster working capital, offering flexibility to issue shares on Nasdaq while paying a 2% commission and standard indemn...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.